Adaptimmune Therapeutics plc (MUN:473A)

Germany · Delayed Price · Currency is EUR

0.0175

-0.0035 (-16.67%)

At close: Mar 13, 2026

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Research, Development and Commercialization of its Novel Cell Therapies	178.03M	60.28M	27.15M	6.15M	3.96M
Research, Development and Commercialization of its Novel Cell Therapies Growth	195.34%	122.05%	341.50%	55.36%	252.76%
Total	178.03M	60.28M	27.15M	6.15M	3.96M
Total Growth	195.34%	122.05%	341.50%	55.36%	252.76%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
United Kingdom	178.03M	60.28M	27.15M	6.15M	3.96M
United Kingdom Growth	195.34%	122.05%	341.50%	55.36%	252.76%
Total	178.03M	60.28M	27.15M	6.15M	3.96M
Total Growth	195.34%	122.05%	341.50%	55.36%	252.76%

Source: S&P Global Market Intelligence.